These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

327 related articles for article (PubMed ID: 27036325)

  • 1. Opportunities for Web-based Drug Repositioning: Searching for Potential Antihypertensive Agents with Hypotension Adverse Events.
    Wang K; Wan M; Wang RS; Weng Z
    J Med Internet Res; 2016 Apr; 18(4):e76. PubMed ID: 27036325
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Pharmacovigilance-based drug repurposing: searching for putative drugs with hypohidrosis or anhidrosis adverse events for use against hyperhidrosis.
    Liu Y; Liu Y; Fan R; Kehriman N; Zhang X; Zhao B; Huang L
    Eur J Med Res; 2023 Feb; 28(1):95. PubMed ID: 36829251
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A Pharmacovigilance Signaling System Based on FDA Regulatory Action and Post-Marketing Adverse Event Reports.
    Hoffman KB; Dimbil M; Tatonetti NP; Kyle RF
    Drug Saf; 2016 Jun; 39(6):561-75. PubMed ID: 26946292
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Data mining methodology for response to hypertension symptomology-application to COVID-19-related pharmacovigilance.
    Xu X; Kawakami J; Millagaha Gedara NI; Riviere JE; Meyer E; Wyckoff GJ; Jaberi-Douraki M
    Elife; 2021 Nov; 10():. PubMed ID: 34812146
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effect of statins on blood pressure: Analysis on adverse events released by FDA.
    You T; Liu XG; Hou XD; Wang XK; Xie HH; Ding F; Yi K; Zhang P; Xie XD
    Clin Exp Hypertens; 2017; 39(4):325-329. PubMed ID: 28513233
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Drug Repurposing Using FDA Adverse Event Reporting System (FAERS) Database.
    Morris R; Ali R; Cheng F
    Curr Drug Targets; 2024; 25(7):454-464. PubMed ID: 38566381
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Mining association patterns of drug-interactions using post marketing FDA's spontaneous reporting data.
    Ibrahim H; Saad A; Abdo A; Sharaf Eldin A
    J Biomed Inform; 2016 Apr; 60():294-308. PubMed ID: 26903152
    [TBL] [Abstract][Full Text] [Related]  

  • 8. An integrative approach using real-world data to identify alternative therapeutic uses of existing drugs.
    Hosomi K; Fujimoto M; Ushio K; Mao L; Kato J; Takada M
    PLoS One; 2018; 13(10):e0204648. PubMed ID: 30300381
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Automatic signal extraction, prioritizing and filtering approaches in detecting post-marketing cardiovascular events associated with targeted cancer drugs from the FDA Adverse Event Reporting System (FAERS).
    Xu R; Wang Q
    J Biomed Inform; 2014 Feb; 47():171-7. PubMed ID: 24177320
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Analysis of Information on Drug Adverse Reactions Using U.S. Food and Drug Administration Adverse Event Reporting System (FAERS)].
    Nango D; Sekizuka T; Goto M; Echizen H
    Yakugaku Zasshi; 2022; 142(4):341-344. PubMed ID: 35370189
    [TBL] [Abstract][Full Text] [Related]  

  • 11. OpenVigil FDA - Inspection of U.S. American Adverse Drug Events Pharmacovigilance Data and Novel Clinical Applications.
    Böhm R; von Hehn L; Herdegen T; Klein HJ; Bruhn O; Petri H; Höcker J
    PLoS One; 2016; 11(6):e0157753. PubMed ID: 27326858
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Can social media data lead to earlier detection of drug-related adverse events?
    Duh MS; Cremieux P; Audenrode MV; Vekeman F; Karner P; Zhang H; Greenberg P
    Pharmacoepidemiol Drug Saf; 2016 Dec; 25(12):1425-1433. PubMed ID: 27601271
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Alleged isotretinoin-associated inflammatory bowel disease: disproportionate reporting by attorneys to the Food and Drug Administration Adverse Event Reporting System.
    Stobaugh DJ; Deepak P; Ehrenpreis ED
    J Am Acad Dermatol; 2013 Sep; 69(3):393-8. PubMed ID: 23683730
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Potential use of data-mining algorithms for the detection of 'surprise' adverse drug reactions.
    Hauben M; Horn S; Reich L
    Drug Saf; 2007; 30(2):143-55. PubMed ID: 17253879
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Drug interactions between antihypertensive drugs and non-steroidal anti-inflammatory agents: a descriptive study using the French Pharmacovigilance database.
    Fournier JP; Sommet A; Durrieu G; Poutrain JC; Lapeyre-Mestre M; Montastruc JL;
    Fundam Clin Pharmacol; 2014 Apr; 28(2):230-5. PubMed ID: 23190210
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Comparing drug safety of hepatitis C therapies using post-market data.
    Huang J; Zhang X; Tong J; Du J; Duan R; Yang L; Moore JH; Tao C; Chen Y
    BMC Med Inform Decis Mak; 2019 Aug; 19(Suppl 4):147. PubMed ID: 31391106
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Target Adverse Event Profiles for Predictive Safety in the Postmarket Setting.
    Schotland P; Racz R; Jackson DB; Soldatos TG; Levin R; Strauss DG; Burkhart K
    Clin Pharmacol Ther; 2021 May; 109(5):1232-1243. PubMed ID: 33090463
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Validation of New Signal Detection Methods for Web Query Log Data Compared to Signal Detection Algorithms Used With FAERS.
    Colilla S; Tov EY; Zhang L; Kurzinger ML; Tcherny-Lessenot S; Penfornis C; Jen S; Gonzalez DS; Caubel P; Welsh S; Juhaeri J
    Drug Saf; 2017 May; 40(5):399-408. PubMed ID: 28155198
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Adverse event reporting patterns of concomitant botanical dietary supplements with CYP3A4 interactive & CYP3A4 non-interactive anticancer drugs in the U.S. Food and Drug Administration Adverse Event Reporting System (FAERS).
    Fahim SM; Mishuk AU; Cheng N; Hansen R; Calderón AI; Qian J
    Expert Opin Drug Saf; 2019 Feb; 18(2):145-152. PubMed ID: 30576263
    [TBL] [Abstract][Full Text] [Related]  

  • 20. ADEpedia-on-OHDSI: A next generation pharmacovigilance signal detection platform using the OHDSI common data model.
    Yu Y; Ruddy KJ; Hong N; Tsuji S; Wen A; Shah ND; Jiang G
    J Biomed Inform; 2019 Mar; 91():103119. PubMed ID: 30738946
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 17.